[Elsevier] Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study

Biafer Post time Yesterday 23:24 | Show all posts |Read mode
This post will be closed automatically in 2026-08-03 23:24
Reward10points


Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

You have to log in before you can reply Login | Register

Points Rules

Senior Member
  • post

  • reply

  • points

    590

Return to the list